The Chronic Fatigue group at Vall d’Hebron Institute of Research (VHIR), led by Dr. José Alegre, presented together with the Catalan company "The Chronic Fatigue group at Vall d'Hebron Institute of Research (VHIR), led by Dr. José Alegre, presented together with the Catalan company VITAE the preliminary results of a clinical trial and a bioassay of Reconnect®, based on the combination of antioxidants Coenzyme Q10 + NADH, with the aim of improving the symptoms of the chronic fatigue syndrome. The clinical trial has demonstrated that the synergetic combination of both natural antioxidants improves the symptoms of the disease and recovery of the biochemical parameters." VITAE the preliminary results of a clinical trial and a biological study with Reconnect®, based on the combination of antioxidants Coenzyme Q10 + NADH, with the aim of improving the symptoms of the Chronic Fatigue Syndrome (CFS).  The clinical trial has demonstrated that the synergetic combination of both natural antioxidants improves the symptoms of the disease and also recovery of biomarker parameters.VHIR researchers conducted the Phase II, double blinded and randomized clinical trial, in 73 patients diagnosed with chronic fatigue syndrome at Vall d’Hebron University Hospital. During 8 weeks, half of them were given CoQ10 + NADH and the other half, placebo, in order to compare the effect of the drug on the cardiac adaptations of patients with chronic fatigue. Furthermore, researchers also measured the intensity of fatigue, pain and sleep problems, before and after the treatment.The results have been recently published in the journal " "http://online.liebertpub.com/doi/abs/10.1089/ars.2014.6181" Antioxidants & Redox Signaling. Dr. Jesús Castro, principal investigator of the Chronic Fatigue group, highlights five benefits of the study: “patients who received this combination of antioxidants showed a significant fatigue reduction, an increase in antioxidant levels and recovery of energy and mitochondrial function in ATP form, an increase of synthase citrate enzyme and a reduction in oxidized lipids, all of them key factors that can contribute to the illness symptomatology”. The next step for VHIR’s researchers and VITAE Co. will be to increase to 300 CFS patients more enrolled in the clinical trial from the Chronic Fatigue Clinical Unit at the Vall d’Hebron Hospital.